3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
82
Pancreatic Neoplasms
33
Stomach Neoplasms
32
Rectal Neoplasms
23
Colonic Neoplasms
22
Neoplasms
20
Neoplasm Metastasis
18
Esophageal Neoplasms
16
Cholangiocarcinoma
14
Burkitt Lymphoma
13
Adenocarcinoma Of Esophagus
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Carcinoma, Non-Small-Cell Lung
12
Biliary Tract Neoplasms
12
Adenocarcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Ovarian Neoplasms
6
Gastrointestinal Neoplasms
6
Leukemia, Biphenotypic, Acute
5
Gallbladder Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Endometrial Neoplasms
5
Advanced Solid Tumors
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lung Neoplasms
4
Leukemia
4
Carcinoma, Renal Cell
4
Appendiceal Neoplasms
4
Urinary Bladder Neoplasms
3
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Leucovorin
×
1 year
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled